BRIEF-Theratechnologies says 82.5 pct of patients achieved the primary endpoint in late-stage trial of HIV drug

* Notified by partner of results for primary end point of

phase iii trial with ibalizumab in patients with multi-drug

resistant hiv-1

Read more